Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Paclitaxel in Refractory SCLC
NCT02551432Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Sep 2015
- Primary completion
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in small cell lung cancer (SCLC), sponsored by Seoul National University Hospital. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02551432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551432.